Evidence map›Paper›PMID 27471492›Full record

ReviewFrontiers in endocrinology2016

Mouse Models Recapitulating Human Adrenocortical Tumors: What Is Lacking?

Felicia Leccia, Marie Batisse-Lignier, Isabelle Sahut-Barnola, Pierre Val, A-Marie Lefrançois-Martinez, Antoine Martinez

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Cardiovascular diagnosis and therapy · 2023
    Article
  4. Article
  5. Review
  6. Update on in-vivo preclinical research models in adrenocortical carcinoma.Current opinion in endocrinology, diabetes, and obesity · 2020
    Review
  7. DLK1/PREF1 marks a novel cell population in the human adrenal cortex.The Journal of steroid biochemistry and molecular biology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Felicia LecciaUMR6293, GReD, INSERM U1103, CNRS, Clermont Université , Clermont-Ferrand , France.
Marie Batisse-LignierUMR6293, GReD, INSERM U1103, CNRS, Clermont Université, Clermont-Ferrand, France; Endocrinology, Diabetology and Metabolic Diseases Department, Centre Hospitalier Universitaire, School of Medicine, Clermont-Ferrand, France.
Isabelle Sahut-BarnolaUMR6293, GReD, INSERM U1103, CNRS, Clermont Université , Clermont-Ferrand , France.
Pierre ValUMR6293, GReD, INSERM U1103, CNRS, Clermont Université , Clermont-Ferrand , France.
A-Marie Lefrançois-MartinezUMR6293, GReD, INSERM U1103, CNRS, Clermont Université , Clermont-Ferrand , France.
Antoine MartinezUMR6293, GReD, INSERM U1103, CNRS, Clermont Université , Clermont-Ferrand , France.
Centre National de la Recherche Scientifique · FRInserm · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRClermont Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenal cortex tumors are divided into benign forms, such as primary hyperplasias and adrenocortical adenomas (ACAs), and malignant forms or adrenocortical carcinomas (ACCs). Primary hyperplasias are rare causes of adrenocorticotropin hormone-independent hypercortisolism. ACAs are the most common type of adrenal gland tumors and they are rarely "functional," i.e., producing steroids. When functional, adenomas result in endocrine disorders, such as Cushing's syndrome (hypercortisolism) or Conn's syndrome (hyperaldosteronism). By contrast, ACCs are extremely rare but highly aggressive tumors that may also lead to hypersecreting syndromes. Genetic analyses of patients with sporadic or familial forms of adrenocortical tumors (ACTs) led to the identification of potentially causative genes, most of them being involved in protein kinase A (PKA), Wnt/β-catenin, and P53 signaling pathways. Development of mouse models is a crucial step to firmly establish the functional significance of candidate genes, to dissect mechanisms leading to tumors and endocrine disorders, and in fine to provide in vivo tools for therapeutic screens. In this article, we will provide an overview on the existing mouse models (xenografted and genetically engineered) of ACTs by focusing on the role of PKA and Wnt/β-catenin pathways in this context. We will discuss the advantages and limitations of models that have been developed heretofore and we will point out necessary improvements in the development of next generation mouse models of adrenal diseases.

Indexed as

adrenalmouse modelsPKAtumorWNT

Identifiers

PMID27471492
PMCPMC4945639
OpenAlexW2461292780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.